Communiqués Lipum AB

Actions

Temps Différé Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
8,9 ^SEK	0,00 %		+6,59 %	+36,50 %

18/06	Lipum AB (publ) achève la partie de l'étude clinique de phase I consacrée aux doses multiples	CI
28/05	Lipum AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

BioStock: Lipum strengthens the board with commercial expertise	05/07	AQ
BioStock: Lipum's CEO comments on multiple-dose results in phase I	20/06	AQ
LIPUM REPORTS FURTHER PROGRESS WHERE THE MULTIPLE DOSE PART OF THE PHASE I CLINICAL STUDY IS COMPLETED	18/06	AQ
Lipum: A new approach to chronic inflammation	29/05	AQ
Lipum Q1 - Initiating preparations for phase II	28/05	AQ
Lipum AB – interim report Q1 for the period January-March 2024	28/05	AQ
BioStock: Flerie Invest continues to support Lipum	13/05	AQ
Lipum receives loan commitment of SEK 20 million	06/05	AQ
BioStock: Lipum's CEO looks ahead after the rights issue	26/04	AQ
Lipum announces final outcome of the rights issue	25/04	AQ
Lipum - Financed and ready to go	24/04	AQ
Lipum announces preliminary outcome of the rights issue	23/04	AQ
Lipum and NorthX Biologics enter into new strategic manufacturing alliance	18/04	AQ
Lipum has been granted funding from Swelife	12/04	AQ
Lipum publishes supplement to the prospectus regarding the rights issue	05/04	AQ
Lipum publishes prospectus regarding the rights issue	03/04	AQ
BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment	03/04	AQ
Lipum AB - Report from the Extraordinary General Meeting	02/04	AQ
Lipum strengthens its protection of the drug candidate SOL-116 through a patent application for inflammation-driven cancer	02/04	AQ
BioStock: Lipum has included first RA patient	22/03	AQ

Aucun résultat pour cette recherche